Recurrent Candida Vulvovaginitis

Vulvovaginal candidiasis (VVC), predominantly caused by Candida albicans, is estimated to affect about 138 million women each year worldwide and 492 over their lifetimes. Recurrent VVC (RVVC), defined as four or more episodes of in a year, increasingly recognized constitutes up 10% the cases VVC. RVVC an important clinical global public health challenge project that will 160 per 2030. significantly affects quality life affected women. Host factors, such underlying immunosuppressive conditions genetic predisposition, are suggested key risk factors for recurrence. However, higher prevalence non-albicans (NAC) species, C. glabrata, tropicalis, krusei, parapsilosis, dubliniensis, guilliermondii, others, which either intrinsically resistant azoles have minimum inhibitory concentrations most antifungal agents, fluconazole, commonly used treatment VVC/RVVC, has been reported. Therefore, remains challenge. Long-term maintenance required avoid recurrence symptoms. Alternative includes boric acid topical amphotericin B; however, they associated with serious side effects, limiting use. The oral echinocandin ibrexafungerp well-tolerated efficacious against vulvovaginitis. presents unique area continued research development.